Intermittent treatment with parathyroid hormone (PTH) increases bone mass in experimental animals and humans. In vitro studies have suggested that the anabolic effect of PTH may be mediated by local growth factors. However, the relevance of these findings to in vivo situations remains unclear. In this study, we examined a time course of daily s.c. injections of hPTH(1-34) on the skeletal concentration of insulin-like growth factor (IGF)-I, IGF-II, and transforming growth factor (TGF-.3) in the proximal tail vertebrae of male rats. PTH caused a time and dose-dependent increase in the bone mineral density of the lumbar spine. This anabolic effect on bone mass was accompanied by progressive increases in bone matrix-associated IGF-I and TGF-fl1. Increases in IGF-I and TGF-1i1 became apparent after four and eight weeks of PTH treatment respectively and persisted through week 12. PTH had no effect on circulating IGF-I, suggesting that the increase of bone matrix IGF-I was due to the local effect of PTH on bone tissue directly rather than to an increase of circulating IGF-I. These data are consistent with the hypothesis that IGF-I and TGF-f81 may play a role as local mediators of the anabolic effects of PTH on bone metabolism. (J. Clin. Invest. 1995. 96:767-774.)
Introduction
Due to the fact that it has been found to stimulate bone formation in laboratory animals (1) (2) (3) (4) (5) , as well as in human beings (6) (7) (8) (9) , intermittent application of parathyroid hormone (PTH)' is currently being investigated for its possible usage in the treatment of various skeletal diseases such as osteoporosis. Many data lead one to the assumption that the anabolic effects of PTH on bone formation occur via an increased synthesis of local growth factors in the bone tissue. Of the various potential anabolic growth factors that could be modulated by PTH, the insulin-like growth factors (IGF) and transforming growth factor beta (TGF-f3) have received the most attention. These factors are found in bone matrix in great abundance and are known stimulators of bone cell replication and matrix synthesis (10) . In osteoblast-enriched cultures of fetal rat bone cells (11) , as well as in rat bone organ cultures (12), PTH has been shown to stimulate IGF-I production at the transcriptional and polypeptide levels. The role of IGF-I as mediator of the anabolic effects of PTH on bone formation is additionally supported by findings that the stimulation of collagen synthesis in cultured rat calvariae after transient PTH administration can be suppressed by antibodies to IGF-I (13) . PTH has also been reported to stimulate the secretion of IGF-II in mouse calvariae cultures ( 12, 14) , whereas Oursler et al. observed a dose-dependent stimulation of TGF-p-bioactivity and TGF-P3-message with PTH in cultures of human osteoblast-like cells (15) .
The relevance of these findings in vivo, however, is largely unknown. The biologically active tissue concentration of growth factors in vivo is not only determined by their local secretion but also by their interactions with extracellular matrix proteins and by adsorption of growth factors derived from the systemic circulation. The extracellular matrix appears to play a critical role in controlling the distribution of growth factors and in the presentation of growth factors to responding cells. Due to its abundant mineralized extracellular matrix, bone offers the opportunity to measure growth factors after they have been sequestered in vivo. To determine whether the intermittent administration of PTH increases anabolic growth factor sequestration into bone matrix and thereby may exert its anabolic effect on bone mass, we quantitatively extracted bone matrix from rat tail vertebrae after various intervals of PTH administration and then assayed the extracts for IGF-I, IGF-II, and TGF-f3. Methods
Experimental design
Male Wistar rats, 60 d old and weighing -160 grams, were randomly allocated into 16 groups, each of which contained six rats. The animals were kept in pairs, had free access to water and were fed a standard diet, containing 1.2% calcium. Daily subcutaneous injections of either vehicle or hPTH( 1-34) (GBF, Braunschweig, Germany) in doses of QDR-1000 instrument (Waltham, MA). The coefficient of variation of the measurements was 1.3%.
Bone matrix extraction
After sacrifice, the proximal 5 tail vertebrae were dissected and freed of adherent soft tissue. Cartilagenous parts and the end plates of each vertebra were carefully removed. Due to the small size of the vertebrae, it was not feasible to completely separate cortical from trabecular bone. However, preceding measurements in rat bones comparing pooled samples of trabecular and cortical bone had revealed similar concentrations of IGF-I, IGF-II, and TGF-/.3 bioactivity in the two compartments. After cleaning, the vertebrae were immersed in liquid nitrogen and mechanically crushed into small fragments of several millimeters in diameter. The fragments were washed repeatedly in cold distilled water until the washings were free of blood and defatted in cold isopropylether. The defatted bone fragments were then ground into smaller particles ,um) in a liquid nitrogen-cooled freezer mill (Raetsch, Haan, Germany).
Fluorometrically measured DNA content in the extracts was below detection limit (-50 ng DNA/20 mg bone powder), indicating minimal cellular contamination of the bone powder.
For each bone sample, four parallel extractions were performed. 20 mg of lyophylized bone powder were placed in microcentrifuge tubes ("Twist-Lock", Eppendorf, Hamburg, Germany) and 1.7 ml of extraction solution (see below) was added. Spectrapor 3 dialysis tubing (3.5-kD cutoff; Spectrum Medical Industries, Houston, TX) was then placed over the tube opening and secured by a melted out tube cap, as described by Overall et al. (16) . The tubes were then inverted and firmly fixed upside down in a circular rack floating on top of the extraction solution (600 ml for 30 tubes). Extraction was achieved by dialysis against 0.05 M tetrasodium EDTA (Serva, Heidelberg, Germany), 4 M Guanidin-HC1 (Sigma, Deisenhofen, Germany), 30 
IGF-I measurements
IGF-I in the tissue extracts was quantified by RIA, using a polyclonal rabbit antibody specific for human IGF-I (Mediagnost, Tubingen, Germany) and recombinant human IGF-I (GroPep, Adelaide, Australia) as a tracer and standard. For each bone sample, extracts from three separate extractions were assayed in duplicate and the means calculated as human IGF-I equivalent. Dilution curves of bone extracts and of rat serum showed good parallelism with the standard curves prepared with the human IGF-I. IGF-binding protein (IGFBP) artifacts were avoided by initial dissociation of IGF from the IGFBP's present using an acidic buffer. Reassociation was then blocked by inducing IGFBP saturation through the addition of excess IGF-II (Mediagnost) (17) . Validation of the assay for bone matrix extractions was performed by showing 1. complete recovery of added unlabeled human IGF-I after preincubation with the extracts, 2. no change in the measurement of endogenous IGF-I in the presence of up to 10 ng/ml IGFBP-3 which was the highest concentration of IGFBP-3 added. IGF-II cross-reactivity in this RIA was found to be less than 0.05% with an inter-assay variation of 5.6% and a sensitivity level of 0.1 ng/ml. As with all samples, serum IGF-I was measured in duplicate using the same assay procedure.
IGF-II measurements
IGF-II was measured by RIA using an anti-IGF-II antibody obtained by immunization of rabbits using the synthetic peptide IGF-II (33) (34) (35) (36) (37) (38) (39) (40) as described earlier (17) . Cross-reactivity of the IGF-ll antibody with IGF-I was < 0.05%. All measurements were calibrated against recombinant human IGF-II (GroPep). Dilution curves of bone extracts and of rat serum were parallel to standard curves prepared with the human IGF-II. Assay conditions were similar to those described for the IGF-I RIA, except that excess IGF-I was used to block interferences caused by IGFBPs. Validation was performed as described for IGF-I. Interassay coefficients of variations were 5.4% at a sensitivity level of 0.1 ng/ml. Serum IGF-II was measured in duplicate using the same assay procedure.
TGF-f3 measurements
Skeletal TGF-,1 was determined by the mink lung cell bioassay (18, 19) and by specific enzyme-linked immunosorbend assays (ELISA) for TGF-fi1 and TGF-f32. For total TGF-,6 bioactivity quantification, mink lung cells (MvlLu, CCL64; American Type Culture Collection, Rockville, MD) were suspended in MEM medium supplemented with 10% FCS (GIBCO, Eggenstein, Germany), plated at 6000 cell/well in 96-well plates and allowed to attach for 4 h. The medium was then aspirated and replaced with serum-free MEM containing bone matrix extracts at a dilution of 1:100 or serial dilutions of TGF-# 1 purified from human platelets (R&D Systems, Minneapolis, MN). Plates were cultured for 21 h followed by pulse labeling with 1 uCi [3H] -thymidine (Amersham Buchler, Braunschweig) for 3 h. Medium was then removed and the cells were fixed with 5% cold trichloracetic acid. Samples were solubilized in 0.25 N sodium hydroxide, and radioactivity was determined by liquid szintillation counting. Immediately before measurement each sample was subjected to a transient acidification at pH2. In accordance with findings from Jennings et al. ( 19) , we observed no inhibition or stimulation of DNA-synthesis with applications of IGF-I, IGF-II, basic and acidic fibroblast growth factor in concentrations of up to 100 ng/ml. Preincubation with two different antibodies capable of simultaneously neutralizing TGF-,61, TGF-/32, and TGF-,B3 (Genzyme, Cambridge, MA, and R&D Systems) with each of these antibodies completely abolished the inhibitory activity of the bone extracts. The inter-assay variation was 29% with a sensitivity of 10 pg/ml. Due to the high interassayvariability, four extractions were performed from each bone sample, followed by measurements of each extract in four individual bioassays.
The concentrations of the different TGF-/3 species in the matrix extracts were estimated as follows: Bone matrix extract were serially diluted up to 200-fold in minimal essential medium. Aliquots of these dilutions were then preincubated for one hour with: 1. medium alone, 2. medium containing 1, 10, or 30 ,ug/ml of a specific antibody which either neutralized TGF-/31, TGF-,B2, or TGF-,/3 or which simultaneously neutralized several TGF-/3 species (all from R&D Systems), 3 . medium containing 30 pg/ml rabbit IgG (R&D Systems) to exclude nonspecific inhibition. Each of the preincubated samples was then assayed in duplicate for its inhibitory effects on DNA-synthesis in the mink lung cell assay as described above. Eight to 10 different dilutions of the matrix extracts were prepared, ranging from dilutions that had a maximal inhibitory effect on DNA-synthesis to dilutions that no longer inhibited DNA-synthesis. In addition, we performed serial dilutions of purified preparations of the particular TGF species against which the antibody was directed. The bioactivity of these dilutions had a similar range as described for the matrix extractions. As with the matrix extracts, these samples were preincubated for one hour either with medium alone, medium containing 1 
Results
As expected, intermittent administration of PTH via daily subcutaneous injections caused a marked time-and dose-dependent increase in the BMD of the lumbar vertebrae. The greatest BMD increase observed (39% above control) was found in the experimental group which received daily PTH injections of 40 I.g/kg PTH for 12 consecutive weeks (Fig. 1) (Fig. 2 A) . Elevated tissue concentrations of IGF-I after PTH-treatment were observed, regardless whether the extracted IGF-I was expressed per mg mineralized bone, mg of nonextractable bone matrix or mg hydroxyproline (Fig. 3, A- C). Thus, this increase in skeletal IGF-I appeared to be due to an authentic increase of IGF-I sequestration into the bone matrix and not to a PTH-induced composition change of the extracellular matrix scaffold. The PTH-mediated elevation of bone IGF-I was superimposed upon a progressive rise of skeletal IGF-I with time. By week 12, the mean IGF-I content in the vehicle-treated bone tissue was 28% higher than in the bones of the 2 wk vehicletreated rats (P = 0.004, ANOVA) (Fig. 2 A) .
In contrast to skeletal IGF-I, circulating IGF-I did not change after treatment with PTH, regardless of the time or dosage of PTH administered (Fig. 4 A) .
Intermittent treatment with PTH had no apparent effect on the skeletal concentration of IGF-H (Fig. 2 B) . The matrix concentrations of IGF-ll in the vehicle-treated animals did not significantly change with time either. There was a remarkable 60% decline in circulating IGF-II during the course of the experiment (P = 0.0001, ANOVA), indicating that the decline in serum IGF-II that can be observed in rats within a few days after birth (21, 22) , continues into early adulthood (Fig. 4 B) . PTH treatment had no effect on circulating IGF-II (Fig. 4 B) (Fig. 2 C) . The (3) 8 (4) 1 2 (5) show that intermittent administration of PTH raises the concenWeeks of treatment tration of extractable IGF-I and TGF-,61 in rat bone.
(Age at end of treatment in months)
PTH had no significant effect on skeletal IGF-II in our study, suggesting that it may specifically increase the concentration of the IGF-I species. However, the variability of the IGF-II measurements was greater than that of the IGF-I measurements, and a small change in the concentration of IGF-H1 may have gone undetected.
Richardson et al. (26) have shown that when radioactive TGF-/3 is applied to the periosteum of skull bone, most of the injected material remains firmly attached to the injection site for up to 16 d after the TGF-,f application. Only a small percentage diffused into distant sites of the bone. This supports the hypothesis that the majority of all locally produced growth factors that attach to bone matrix remains attached there and only move into deeper layers of the bone as new matrix is deposited on top of the old matrix. Since our extraction method does not discriminate between bone matrix formed before and after the onset of the PTH treatment, PTH-induced changes in the amount of extractable growth factors may not become apparent to their full extent, until the old bone matrix has been completely replaced by matrix that has been formed during the time of the PTH administration. Published dynamic histomorphometry data on 60-d-old rats suggest that a minimum of 1 or 2 mo is required for complete bone turnover of the lumbar vertebrae (27, 28) . This may explain why significant increases in extractable growth factors in our study were observed as late as 4 and 8 wk after the onset of the PTH treatment.
We cannot completely dismiss the possibility that a small portion of endogenous IGF or TGF-P might have escaped our extraction procedure. Nevertheless, there are several reasons supporting the belief that the extraction of the IGFs and TGF-0 in our study was quantitative. Losses due to nonspecific binding, denaturation or degradation were minimal as judged by the complete recovery of exogenously added growth factors. No additional IGF or TGF-,f release using a longer extraction period or other modifications of the extraction procedure was observed. Furthermore, even further digestion with high-grade collagenase produced no additional release of the growth factors assayed in this study. Nonwithstanding the differences in the extraction method and in the specificities of the IGF-I assays, the skeletal concentrations of IGF-I, -II and TGF-,6 bioactivity per mg mineralized bone matrix reported here are in acceptable agreement with those previously reported by Finkelman et al. for rat bone matrix (23, 24) .
Apart from the extraction procedure, the measurement of the IGFs and TGF-f3 is not unproblematic. The measurement of the IGFs is particularly challenging due to the presence of high-affinity IGF-binding proteins (IGFBPs). In preliminary experiments, acidic size exclusion chromatography had only a low precision with our samples, and acid-ethanol extractions frequently fail to reliably remove these interfering binding proteins ( 17, (29) (30) (31) In our study, using highly specific antibodies for IGF-I and IGF-ll, the effects of IGFBPs after acidification were suppressed by the addition of an excess of the nonmeasured peptide (IGF-I in the IGF-ll assay and vice versa). This results in specific IGFBP binding and prevents the binding of the tracer to the IGFBPs present in the sample (29) . Validation for our samples demonstrated that this method completely prevented any interference of the IGFBPs with the IGF measurements.
All of our measurements were performed with antibodies against human proteins, and the results are expressed as human growth factor equivalent. Since exact figures on the cross-reactivity of the rat growth factors in our assays are unknown, it is possible that the correct absolute concentrations of these peptides may be different from the ones reported here. However (11) (12) (13) (14) (15) In the study presented here, we did not observe any increase in serum IGF-I during the course of the experiment. Based on the 95% confidence intervals of the IGF-I measurements, increases of > 10% should have been readily detected. Experience with subcutaneous growth hormone injections have shown that IGF-I levels in blood slowly rise up to 24 h after the injections and remain at a plateau for at least one day (36, 37) . It is therefore unlikely that we might have missed PTH-induced increases in circulating IGF-I by our blood sampling schedule. Thus, at least for IGF-I, the present report does not provide any evidence for a systemic contribution of the PTH-induced increases in skeletal growth factors.
Both IGF-I and TGF-f31 are potent anabolic growth factors for bone in vivo and in vitro and may thus function as local determinants of bone formation in vivo (10) . Assuming that our measurements reflect the locally effective tissue concentrations of these factors at the time when the extracted bone matrix was formed, our data are consistent with the hypothesis that (24) . These differential effects on the concentration of two major anabolic growth factors may be one of the reasons, why in spite of a similar increase in bone resorption, bone balance is positive with intermittent PTH treatment, but negative with estrogen withdrawal. Nevertheless, our study does not exclude that the increases in IGF-I and TGF-f31 and in bone mass after PTH treatment may have been coincidental, and additional studies will be necessary to prove a causal relationship. It should also be noted that, in contrast to the lumbar BMD, the effects of PTH on bone IGF-I and TGF-f31 in the tail vertebrae lacked a clear dose response, but this lack of congruency may be sufficiently explained by the considerably greater variability of the growth factor measurements as compared to that of the BMD measurements.
Due to their high bone turnover, rats are ideally suited for examining hormonal effects on the concentration of bone matrix-associated growth factors. However, one should be aware that the composition of growth factors in human bone is different from that in rat bone. In particular, bones of growing rats have more abundant IGF-I than IGF-H1, whereas the opposite is true in adult human bone tissue (23, 24, 38 
